Abstract
Gemtuzumab ozogamicin (GO) and inotuzumab ozogamicin (InO) are indicated for newly diagnosed or relapsed/refractory CD33-positive acute myeloid leukem......
小提示:本篇文献需要登录阅读全文,点击跳转登录